Bicycle Therapeutics announced a 30% workforce reduction and a strategic de‑prioritization of its Padcev challenger following an unexpected regulatory setback that extended the path to approval. The company said it will halve operating expenses to preserve cash and end work on two early trials tied to the lead program. Management framed the restructuring as necessary to extend runway while re‑focusing resources on core assets and alternative strategies. One‑sentence clarification: Bicycle’s proprietary bicyclic peptide platform aims to deliver targeted payloads similar to ADCs but with small‑molecule-like properties. Why it matters: the moves illustrate how regulatory delays cascade into program mothballing and headcount reductions in small biotechs, and they underscore the program‑level risk investors weigh when valuing clinical‑stage companies.